文献速递糖尿病

自动胰岛素输注系统在2型糖尿病中的系统综述与荟萃分析

Automated Insulin Delivery Systems in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.
PubMed 文献 · Diabetes Care · 2026-01-01

该系统综述与荟萃分析纳入9项研究共1530例需要胰岛素的2型糖尿病患者,评估自动胰岛素输注(AID)系统对血糖结局的影响。单臂荟萃分析显示,AID系统显著提高葡萄糖目标范围内时间(TIR)16.06%,降低高血糖时间(TAR)15.90%,降低HbA1c 1.27%,降低平均血糖21.34 mg/dL,并适度降低低血糖时间(TBR)。结论支持在未来的2型糖尿病管理指南中推荐使用AID系统。

要点

  • AID系统使2型糖尿病患者TIR提高16.06%,HbA1c降低1.27%。
  • AID系统降低TAR 15.90%和平均血糖21.34 mg/dL,并适度降低TBR。
  • 研究支持在2型糖尿病管理指南中推荐AID系统。

核心结论

  • AID系统改善了需要胰岛素治疗的多样化2型糖尿病患者的血糖控制,并减少了低血糖。
  • 这些发现支持在未来的2型糖尿病管理指南中推荐使用AID系统。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Embase、Cochrane Library和ClinicalTrials.gov至2025年3月10日。
  • 纳入9项研究共1530例需要胰岛素的2型糖尿病患者,报告持续葡萄糖监测结局。
  • 采用随机效应模型进行单臂荟萃分析,研究注册于PROSPERO(CRD420251036184)。

主要发现

  • AID系统使TIR(3.9-10.0 mmol/L)显著增加16.06%(95% CI 10.48-21.65)。
  • AID系统使TAR(>10.0 mmol/L)变化-15.90%(95% CI -21.44至-10.36)。
  • AID系统使HbA1c变化-1.27%(95% CI -2.06至-0.48)。
  • AID系统使平均血糖变化-21.34 mg/dL(95% CI -32.06至-10.62)或-1.19 mmol/L(95% CI -1.78至-0.59)。
  • TBR(<3.9 mmol/L)有适度但显著的降低,体重或BMI无变化。

关键数值与推荐

  • TIR目标范围定义为3.9-10.0 mmol/L(70-180 mg/dL)。
  • TAR定义为>10.0 mmol/L(>180 mg/dL),TBR定义为<3.9 mmol/L(<70 mg/dL)。

临床怎么用

  • 对于需要胰岛素治疗的2型糖尿病患者,可考虑使用AID系统以改善血糖控制并减少低血糖。

局限性

  • 研究设计异质性大,仅纳入3项随机对照试验。
  • 存在对缺失数据的插补。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Automated insulin delivery (AID) systems are the standard of care in type 1 diabetes. Recent studies suggest benefits of these systems for people with type 2 diabetes, as well. PURPOSE: To evaluate the effects of AID systems on glycemic outcomes in people with type 2 diabetes requiring insulin. DATA SOURCES: The PubMed, Embase, Cochrane Library, and ClinicalTrials.gov databases were searched through 10 March 2025. This study was registered with PROSPERO (CRD420251036184). STUDY SELECTION: Nine studies (n = 1,530 participants) were included that evaluated AID systems in people with type 2 diabetes reporting continuous glucose monitoring outcomes. DATA EXTRACTION: Data were collected on study characteristics and outcomes including time in range (TIR) (3.9-10.0 mmol/L [70-180 mg/dL]), time above range (TAR) (>10.0 mmol/L [>180 mg/dL]), time below range (TBR) (<3.9 mmol/L [<70 mg/dL]), mean glucose, and HbA1c. We performed a single-arm meta-analysis using a random-effects model. DATA SYNTHESIS: AID systems significantly increased TIR by 16.06% (95% CI 10.48-21.65), changed TAR by -15.90% (95% CI -21.44 to -10.36), changed HbA1c by -1.27% (95% CI -2.06 to -0.48), and changed mean glucose by -21.34 mg/dL (95% CI -32.06 to -10.62) or 1.19 mmol/L (95% CI -1.78 to -0.59). There was a modest yet significant reduction in TBR. There were no changes in body weight or BMI. LIMITATIONS: Heterogeneous study designs, including only three randomized controlled trials, and imputed missing data. CONCLUSIONS: AID systems improved glucose control in a diverse population of individuals with type 2 diabetes requiring insulin therapy with reduction in hypoglycemia. These findings support recommendations for AID systems use in future type 2 diabetes management guidelines.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Hespanhol LC, Agarwal S, Carvalhal G, et al. Automated Insulin Delivery Systems in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis. Diabetes Care. 2026. PMID: 41940799. doi:10.2337/dc25-2435

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。